Medtronic MiniMed Paradigm Veo Insulin Pump Recalled for 55,724 Units (2026)
Medtronic MiniMed recalls 55,724 Paradigm REAL-Time Veo insulin pumps distributed worldwide. The pumps can deliver too much insulin when raised or too little when lowered relative to the infusion site due to gravity-driven pressure changes. Patients should stop using the device and contact Medtronic MiniMed or their healthcare provider for instructions and refunds.
Quick Facts at a Glance
Recall Date
February 13, 2026
Hazard Level
HIGH
Brand
Medtronic MiniMed
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL
Hazard Information
All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and hydrodynamic pressures. Insulin over-delivery, which can occur when the pump is elevated relative to the infusion site, can result in severe hypoglycemia, altered mental status, seizure, coma, or death. An under-delivery of insulin, which can occur at lowered pump height conditions relative to the infusion site, can result in severe hyperglycemia, dehydration, diabetic ketoacidosis, or death.
What You Should Do
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Medtronic MiniMed, Inc. or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
No spamUnsubscribe anytime
About This Product
Insulin pumps deliver continuous insulin to help manage diabetes. The Paradigm Veo system is part of Medtronic’s older Paradigm line and 600/700 series.
Why This Is Dangerous
The device’s insulin delivery can be incorrect due to pump height changes, affecting pressure at the infusion site. Over-delivery risks hypoglycemia and death; under-delivery risks hyperglycemia and death.
Industry Context
This recall is not described as part of a broader safety pattern in the provided data.
Real-World Impact
Patients could experience dangerous blood glucose fluctuations. Immediate action is required to prevent harm and stabilize treatment.
Practical Guidance
How to identify if yours is affected
1. Locate model number on device label (MMT-554 or MMT-754).
2. Confirm Paradigm REAL-Time Veo branding.
3. Check the FDA recall page for Z-1752-2026 and Medtronic communications.
Where to find product info
FDA enforcement page and Medtronic recall notices on medtronic.com
What timeline to expect
Refunds or replacements typically follow manufacturer guidance within weeks to months.
If the manufacturer is unresponsive
Escalate to the consumer protection agency in your country (eg, CPSC in the U.S.).
Seek assistance from your healthcare provider.
Document all contact attempts and keep copies of correspondence.
How to prevent similar issues
Stay aware of recall notices for any medical device.
Ask healthcare providers about safer pump options if you require continued insulin delivery.
Keep a current list of emergency contacts and glucose monitoring supplies.
Documentation advice
Keep device label, model numbers, recall notices, and all correspondence with manufacturer. Document symptoms and medical visits related to recall events.
Product Details
Model numbers: MMT-554 and MMT-754. Product: Paradigm REAL-Time Veo Insulin Pump. Sold worldwide. Recall date: 2026-02-13. Quantity: 55,724. Manufacturer: Medtronic MiniMed, Inc. Price: Not disclosed. Country of origin: Unknown.
Reported Incidents
No injuries or incidents have been reported.
Key Facts
55,724 units recalled worldwide
Paradigm REAL-Time Veo insulin pumps included (MMT-554, MMT-754)
Over-delivery when pump is raised; under-delivery when lowered
No injuries or incidents reported (per recall)
Stop using the device and await instructions from Medtronic MiniMed
Medtronic recalled 453,144 MiniMed 780G insulin pumps worldwide after reports of unintended insulin delivery when the pump height changes relative to the infusion site. The defect stems from gravity-driven pressure changes affecting hydrostatic delivery. Patients and caregivers should stop using the devices immediately and follow the recall notice, contacting Medtronic MiniMed or their clinician’s
Medtronic recalled 13,429 MiniMed insulin pumps worldwide after identifying unintended insulin delivery errors. The issue occurs when the pump height relative to the infusion site changes, causing over-delivery or under-delivery of insulin. Patients should stop using the device and contact Medtronic for instructions.
Medtronic MiniMed recalled 24,946 MiniMed 740G insulin pumps worldwide after identifying unintended insulin delivery when the pump height changes relative to the infusion site. The defect can cause over-delivery or under-delivery of insulin due to gravity-driven pressure changes. Patients should stop using the device and contact Medtronic MiniMed for instructions on recall steps, refunds or a swap
Medtronic MiniMed recalled 26,647 Paradigm REAL-Time Revel insulin pumps distributed worldwide, including in the United States. A design flaw can cause insulin to be over- or under-delivered when the pump height changes relative to the infusion site. Patients and health providers should stop using the device immediately and follow the manufacturer’s recall instructions. The recall covers Paradigm,
Medtronic MiniMed recalled 37,458 insulin pumps sold worldwide through healthcare providers, including the MiniMed 720G, after finding that a pump raised above or lowered relative to the infusion site can deliver insulin too much or too little. The defect stems from changes in gravitational force affecting hydrostatic and hydrodynamic pressures at the infusion site. Patients should stop using the
Medtronic MiniMed recalled 29,074 Paradigm Real-Time insulin pumps worldwide. The devices may deliver insulin improperly when the pump is elevated or lowered relative to the infusion site due to gravitational effects. Patients should stop using the pumps immediately and follow recall instructions from the manufacturer and their healthcare provider.
Medtronic MiniMed recalled 73,656 Paradigm insulin pumps sold worldwide, including broad U.S. distribution, after a risk of unintended insulin delivery. The issue affects Paradigm, 600-series and BLE 700-series pumps. It can cause life-threatening highs or lows in insulin delivery. Stop using the device and follow recall instructions immediately.
Medtronic MiniMed recalled 60,880 insulin pumps sold worldwide through healthcare providers and medical distributors, including the MiniMed 630G line. The defect is gravity related and can cause insulin over-delivery or under-delivery when the pump height changes relative to the infusion site. Patients should stop using the pumps immediately and follow recall instructions.